Quarterly ResultMay 13, 2026, 06:41 AM
Aprea Therapeutics Secures $30M; APR-1051 Shows PRs
AI Summary
Aprea Therapeutics reported its first quarter 2026 financial results, highlighted by the successful closing of an oversubscribed $30 million private placement. The company also provided an encouraging update on its ACESOT-1051 trial for WEE1 inhibitor APR-1051, noting two partial responses and good tolerability. This financing significantly strengthens the balance sheet, extending the cash runway into Q1 2028.
Key Highlights
- Closed an oversubscribed $30 million private placement on March 31, 2026.
- Reported $46.5 million in cash and cash equivalents as of March 31, 2026.
- Anticipates cash runway into Q1 2028.
- Observed two partial responses (PR) in the ACESOT-1051 trial for APR-1051.
- Treated 28 patients in the ACESOT-1051 trial to date.
- Reported an operating loss of $3.4 million for Q1 2026.
- R&D expenses decreased to $1.6 million for Q1 2026 from $2.5 million in Q1 2025.
- Net loss of $3.3 million, or ($0.22) per basic share, for Q1 2026.
Price Impact
More from APRE